STAT+: Better Therapeutics data on apps’ benefit with GLP-1s, Orexo hits a snag
In the latest edition of STAT's Health Tech newsletter: Better Therapeutics data on apps' benefit with GLP-1s, Orexo’s app hits a snag, FDA to set up digital health advisory committee.
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.
Diabetes: Better shows data on app’s benefit with GLP-1s
Better Therapeutics announced top-line data suggesting that its prescription app for diabetes treatment, AspyreRx, can boost the impact of GLP-1 diabetes treatments. According to the release, a subgroup analysis of 160 participants in its pivotal trial on GLP-1 treatment found that the behavior modification app produced statistically significant reductions in A1C compared to a control group.
What's Your Reaction?
